TL;DR: BioLife received U.S. Patent 12,667,605 B2 on September 10, 2026 for a dissolvable effervescent tablet technology designed to protect peptide medicines through digestion and support absorption.

BioLife announced in Paris on September 10, 2026 that the United States Patent and Trademark Office granted U.S. Patent 12,667,605 B2 for its effervescent oral peptide delivery technology, according to EurekAlert!. The announcement described the technology as designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease. The company uses the internal name OralMatrix for the invention, according to BioSpace.

The patent grant was reported the same day by multiple outlets covering pharmaceutical technology, including BioSpace and Drug Target Review. BioSpace summarized the company statement that preclinical studies demonstrated measurable systemic semaglutide exposure following oral administration. Drug Target Review reported that the granted patent covers an effervescent delivery approach developed for GLP-1 therapies.

The development remains investigational. The company stated that the technology is in development and is not approved for the treatment of any disease, according to EurekAlert!.

What the new U.S. patent covers

The granted U.S. claims extend across the GLP-1 class, according to EurekAlert!. The listed medicines are semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. That scope means the patent is not limited to one commercial product.

Patent protection runs into 2042, according to BioSpace. Additional patent applications are pending internationally. The company said its technology portfolio and related patent estate have been independently developed and are wholly owned, according to EurekAlert!.

Dr. Farid Bennis is the named inventor on U.S. Patent No. 12,667,605 B2, according to EurekAlert!. Bennis is the founder of BioLife and chairman of the pharmaceutical company Laprophan Group. Laprophan Group was established in 1949 and is present in more than 40 countries.

Bennis is described as an expert in effervescence research and technology, according to BioSpace. Over more than 35 years, he has developed pharmaceutical effervescence technologies across multiple therapeutic areas, resulting in patented inventions and commercialized healthcare products. The oral peptide program reflects nearly two decades of work devoted to oral peptide delivery.

How the effervescent tablet is designed to work

The technology uses a dissolvable effervescent tablet format, according to EurekAlert!. When dissolved, the tablet is designed to create a gastric buffer. The company describes that buffer as intended to help protect peptide therapeutics through the digestive system and support their absorption.

The approach differs from methods that rely on special coatings or absorption-enhancing ingredients, according to BioSpace. Instead of adding those components, BioLife uses the effervescent formulation itself to create conditions intended to help the peptide remain intact during passage through the gastrointestinal tract.

First-generation oral GLP-1 medicines have demonstrated the value of oral administration, according to EurekAlert!. The same announcement said those medicines also underscored the fundamental challenge in peptide drug development: protecting large peptide molecules as they move through the gastrointestinal tract.

Drug Target Review explained that peptides can be vulnerable to degradation in the gastrointestinal tract. The publication reported that their larger molecular structures can make it difficult for them to cross biological membranes and reach the bloodstream in sufficient quantities. That vulnerability helps explain why a molecule may show biological activity in laboratory or injectable studies yet prove harder to develop as an oral medicine.

The stomach and intestine are chemically active environments, according to Drug Target Review. The publication reported that a formulation therefore needs to protect the peptide long enough for an active form to reach a site where absorption can occur. Absorption presents another hurdle because only a fraction of a surviving peptide may cross into the bloodstream.

Preclinical result reported for semaglutide

Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, according to EurekAlert!. The company described that finding as providing in vivo proof of concept for the approach.

The technology description states that the same dissolvable tablet format is designed to support oral delivery of peptide medicines including GLP-1 therapies, according to BioSpace. The reported systemic exposure involved semaglutide administered orally in preclinical testing.

Drug Target Review reported that the immediate significance of the patent is intellectual property protection rather than evidence of a new approved medicine. The publication stated that further evidence will be needed to establish performance across different peptide molecules, doses and patient populations.

The questions identified by Drug Target Review include how effectively the technology protects different peptide molecules, how much active drug reaches systemic circulation, and whether that exposure is sufficient to produce a predictable therapeutic response. Those questions concern future clinical development and regulatory assessment, not the completed patent grant.

Why oral delivery matters for GLP-1 medicines

The announcement comes as demand for GLP-1 medicines continues to accelerate, according to EurekAlert!. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market. The market figures were attributed to IQVIA data presented at AMCP Annual 2026 and reported by Managed Healthcare Executive.

As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow, according to BioSpace. Oral administration offers an injection-free route, while effective oral exposure remains technically complex to achieve.

Drug Target Review reported that the pharmaceutical industry is investing heavily in peptide medicines, particularly GLP-1 therapies for obesity and diabetes. The publication said finding ways to protect peptides during passage through digestion could influence both existing GLP-1 medicines and future peptide programs.

Oral peptide drug delivery remains an important area of innovation as companies evaluate increasingly sophisticated therapies for obesity, diabetes and metabolic disease, according to EurekAlert!. The company said the opportunity extends beyond current GLP-1 medicines toward future generations of peptide therapeutics.

Decades of effervescence work behind OralMatrix

BioLife said the technology was built on more than 35 years of pharmaceutical effervescence expertise, according to EurekAlert!. The development program builds on nearly 20 years of research.

That history includes human clinical studies with oral insulin formulations, according to BioSpace. The collaborators named for the development program are Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac.

Drug Target Review reported that the company’s development history provides context for the technology. It also stated that translation from preclinical exposure to clinically meaningful drug levels and therapeutic effects remains the more important question for researchers.

Bennis said GLP-1 medicines changed treatment for obesity and metabolic disease while better oral options are still needed, according to EurekAlert!. He said the patent reflects scientific work focused on helping peptide molecules pass through the digestive system intact for current therapies and future peptide therapeutics.

The company said the patented approach was developed to explore what comes next after first-generation oral GLP-1 medicines, according to BioSpace. That framing places OralMatrix as a delivery platform under investigation, rather than a marketed treatment.

Ownership, regulatory status and international plans

BioLife develops oral delivery technologies for peptide medicines, according to EurekAlert!. Its stated areas of expertise are pharmaceutical effervescence, formulation science and oral peptide research.

The company’s technology portfolio and related patent estate have been independently developed and are wholly owned, according to BioSpace. The U.S. grant provides protection into 2042, with further applications pending internationally.

Drug Target Review reported that the next stage will be movement from proof of concept toward clinical development and regulatory assessment. Researchers and developers will look for evidence on protection of different molecules, systemic exposure and therapeutic response.

For now, the completed event is the September 10, 2026 announcement that the United States Patent and Trademark Office granted U.S. Patent 12,667,605 B2. The underlying medicines that might use the delivery system remain subject to separate development, clinical testing and regulatory review.

Sources referenced